Home/Pipeline/Tirzepatide (Mounjaro)

Tirzepatide (Mounjaro)

Type 2 Diabetes

ApprovedCommercial

Key Facts

Indication

Type 2 Diabetes

Phase

Approved

Status

Commercial

Company

Eli Lilly

About Eli Lilly

Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.

View full company profile

Therapeutic Areas

Diabetes Oncology Immunology Neuroscience Obesity Cardiovascular

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Orforglipron	Eli Lilly	Phase 3	Active
Trulicity (dulaglutide)	Eli Lilly	Approved	Commercial
Forxiga	AstraZeneca	Approved	Commercial
siRNA GalXC-GYS2	Novo Nordisk	Phase 1	Active
Amylin/semaglutide combination	Novo Nordisk	Phase 3	Active
Lipaglyn	Zydus Lifesciences	Approved	Commercial
LBS-009	Belite Bio	Preclinical	Active
Jentadueto (Linagliptin/Metformin)	Yuhan	Approved	Commercial
Nesina (Alogliptin)	Yuhan	Approved	Commercial
Metformin & Combinations	Ipca Laboratories	Commercial	Active
GSBR-1290	Structure Therapeutics	Phase 2	Active, not recruiting
Metformin	Granules India	Approved/Commercial	Active